Mural Oncology Narrows Losses Amid Strategic Pivot, XOMA Acquisition Looms

TL;DR

**Mural Oncology is essentially liquidating its R&D and selling off, so take the $2.035/share and run, because there's no drug pipeline left.**

AI Summary

Mural Oncology plc reported a significant decrease in net loss for the three months ended September 30, 2025, to $3.71 million, a substantial improvement from the $31.76 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $84.83 million, down from $94.24 million in 2024. This reduction in losses is primarily due to a drastic cut in research and development (R&D) expenses, which plummeted from $27.59 million in Q3 2024 to a negative $4.29 million in Q3 2025, and from $81.99 million to $46.41 million for the nine-month period. The company ceased all clinical development of nemvaleukin and preclinical programs by June 2025 following the failure of its Phase 3 ARTISTRY-7 trial. Mural Oncology is currently pursuing an acquisition by XOMA Royalty Corporation for $2.035 per share, based on a closing net cash target of $36.2 million. Cash and cash equivalents decreased from $115.46 million at December 31, 2024, to $58.87 million at September 30, 2025, reflecting significant cash burn from operating activities, which used $86.64 million over the nine months.

Why It Matters

This filing signals a critical juncture for Mural Oncology, as its future hinges on the proposed acquisition by XOMA Royalty Corporation. For investors, the $2.035 per share cash offer provides a clear, albeit potentially limited, exit strategy following the complete cessation of all drug development programs. Employees face uncertainty, as the corporate restructuring and headcount reduction, coupled with the discontinuation of all R&D, indicate a significant shift away from its prior operational model. Customers (patients) will no longer see nemvaleukin or other pipeline candidates developed by Mural. The broader market will observe this as a case study in the high-risk, high-reward nature of biopharmaceutical development, where clinical trial failures can lead to rapid strategic pivots and company acquisitions, impacting competitive dynamics in the oncology space.

Risk Assessment

Risk Level: high — The risk level is high due to the company's complete cessation of all clinical and preclinical development programs by June 2025, as stated in Note 1. This means Mural Oncology has no ongoing operations or revenue-generating products. The company's future is entirely dependent on the consummation of the proposed acquisition by XOMA Royalty Corporation, which carries inherent risks of failure, as highlighted in the 'Summary of the Material Risks' section.

Analyst Insight

Investors should carefully evaluate the $2.035 per share offer from XOMA Royalty Corporation against the company's current cash position and the significant risks associated with its lack of ongoing operations. Given the complete cessation of R&D and the company's reliance on the acquisition, accepting the offer appears to be the most prudent course of action to realize value, as the alternative could be a dissolution and liquidation with an uncertain distribution amount.

Financial Highlights

debt To Equity

0.19

revenue

$0

operating Margin

N/A

total Assets

$65.76M

total Debt

$10.57M

net Income

-$3.71M

eps

-$0.21

gross Margin

N/A

cash Position

$58.87M

revenue Growth

N/A

Key Numbers

• $3.71M — Net Loss (Q3 2025) (Significantly reduced from $31.76M in Q3 2024 due to R&D cessation.)
• $84.83M — Net Loss (YTD Sep 2025) (Lower than $94.24M in YTD Sep 2024, reflecting cost-cutting.)
• $4.29M — Research and Development Expense (Q3 2025) (Negative due to adjustments, down from $27.59M in Q3 2024, reflecting program termination.)
• $46.41M — Research and Development Expense (YTD Sep 2025) (Reduced from $81.99M in YTD Sep 2024, indicating significant R&D cuts.)
• $17.49M — Restructuring and Impairment Expense (YTD Sep 2025) (New expense reflecting corporate restructuring and asset write-offs.)
• $58.87M — Cash and Cash Equivalents (Sep 30, 2025) (Decreased from $115.46M at Dec 31, 2024, indicating ongoing cash burn.)
• $86.64M — Cash Flows Used in Operating Activities (YTD Sep 2025) (Significant cash outflow, though less than $96.78M in YTD Sep 2024.)
• $2.035 — Acquisition Price Per Share (Base cash price offered by XOMA Royalty Corporation.)
• $36.2M — Target Closing Net Cash (Basis for the $2.035 per share acquisition price.)
• 17,344,486 — Ordinary Shares Outstanding (Nov 3, 2025) (Total shares outstanding as of a recent date.)

Key Players & Entities

• Mural Oncology plc (company) — Registrant and oncology company
• XOMA Royalty Corporation (company) — Acquirer in the proposed transaction
• nemvaleukin alfa (drug) — Product candidate whose development was discontinued
• ARTISTRY-7 trial (event) — Phase 3 trial that failed its primary endpoint
• Alkermes plc (company) — Former Parent company
• September 30, 2025 (date) — End of the reported quarterly period
• November 3, 2025 (date) — Date for outstanding ordinary shares count
• Nasdaq Global Market (market) — Exchange where ordinary shares are registered
• Ireland (country) — Jurisdiction of incorporation
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Clinical Trial Failure and Program Termination [high — operational]: The company ceased all clinical development of nemvaleukin and preclinical programs by June 2025 following the failure of its Phase 3 ARTISTRY-7 trial. This led to a significant reduction in R&D expenses but also necessitated a restructuring and impairment charge of $17.49 million for the nine months ended September 30, 2025.
• Significant Cash Burn and Declining Cash Position [high — financial]: Cash and cash equivalents decreased from $115.46 million at December 31, 2024, to $58.87 million at September 30, 2025. Operating activities consumed $86.64 million in cash over the nine months, indicating a substantial burn rate that could impact future operations if not managed.
• Acquisition Uncertainty and Valuation [high — financial]: Mural Oncology is pursuing an acquisition by XOMA Royalty Corporation for $2.035 per share, contingent on a closing net cash target of $36.2 million. The success and final valuation of this acquisition are critical for shareholders, given the company's current financial trajectory.
• Negative R&D Expense in Q3 2025 [medium — operational]: Research and development expenses were reported as a negative $4.29 million for Q3 2025, a drastic change from $27.59 million in Q3 2024. While this reflects the cessation of programs, the unusual negative figure may require further investor scrutiny for its accounting implications.
• Dependence on Acquisition for Shareholder Value [high — financial]: With the cessation of its primary development programs, the company's future value is heavily tied to the successful completion of the XOMA acquisition. Any disruption or renegotiation of this deal poses a significant risk to shareholder returns.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often face binary outcomes with clinical trial successes or failures. Mural Oncology's situation reflects a common challenge where pipeline setbacks can lead to strategic pivots or acquisitions.

Regulatory Implications

The cessation of clinical trials and preclinical programs due to trial failure implies that the company has navigated regulatory feedback on its lead candidate. Future regulatory interactions would primarily pertain to any ongoing compliance or reporting requirements related to past activities and the ongoing acquisition process.

What Investors Should Do

1. Monitor the progress and finalization of the XOMA acquisition.
2. Analyze the implications of the negative R&D expense in Q3 2025.
3. Assess the company's cash runway post-acquisition.
4. Evaluate the restructuring and impairment charges.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significantly reduced net loss of $3.71M, driven by R&D program cessation. Cash and cash equivalents stood at $58.87M.
• 2025-06-30: Program Cessation — Mural Oncology ceased all clinical development of nemvaleukin and preclinical programs following the failure of the ARTISTRY-7 trial.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $31.76M, with R&D expenses of $27.59M, highlighting the substantial cost reduction in the current period.
• 2024-12-31: End of Fiscal Year 2024 — Company held $115.46M in cash and cash equivalents, indicating a significant decrease in liquidity by Q3 2025.

Glossary

Accumulated deficit

The total net losses of a company over its lifetime that have not been offset by net income. (Indicates the company has historically operated at a loss, with a deficit of $244.20M as of September 30, 2025.)

Restructuring and impairment

Costs associated with significant organizational changes, such as layoffs or closing facilities, and the write-down of asset values. (A new expense category for YTD Sep 2025, totaling $17.49M, reflecting the company's strategic shift and asset write-offs due to program termination.)

Right-of-use assets

Assets representing a lessee's right to use an identified asset for a specified period of time, typically related to leases. (These assets decreased from $6.78M at Dec 31, 2024, to $3.13M at Sep 30, 2025, likely due to lease terminations or expirations as part of restructuring.)

Net cash target

A specific amount of net cash that a company must have at the closing of a transaction, often used in M&A deals. (The acquisition price of $2.035 per share is based on a target closing net cash of $36.2 million, making this a critical metric for the deal's finalization.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Mural Oncology has drastically reduced its net loss from $94.24 million to $84.83 million, primarily driven by a significant cut in R&D expenses from $81.99 million to $46.41 million. This reduction is a direct consequence of terminating its development programs. The company also incurred a new restructuring and impairment expense of $17.49 million in the current period. While operating expenses have decreased, cash burn from operations remains substantial, leading to a lower cash position compared to the end of the previous fiscal year.

Key Financial Figures

• $0.01 — stered Ordinary shares, nominal value $0.01 per share MURA The Nasdaq Global Ma

Filing Documents

• mura-20250930.htm (10-Q) — 2470KB
• mura-ex31_1.htm (EX-31.1) — 18KB
• mura-ex31_2.htm (EX-31.2) — 18KB
• mura-ex32_1.htm (EX-32.1) — 11KB
• mura-ex32_2.htm (EX-32.2) — 11KB
• 0001193125-25-268122.txt ( ) — 8046KB
• mura-20250930.xsd (EX-101.SCH) — 896KB
• mura-20250930_htm.xml (XML) — 1325KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations and Comprehensive Loss 5 Condensed Consolidated Statements of Equity (Deficit) 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II. OTHER INFORMATION 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 5. Other Information 79 Item 6. Exhibits 80

Signatures

Signatures 81 1 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements contained in this Quarterly Report, other than statements of historical facts, including statements about future events, future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations, are forward-looking statements that involve certain risks and uncertainties. Use of the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "seeks," "intends," "evaluates," "pursues," "anticipates," "continues," "designs," "impacts," "affects," "forecasts," "target," "outlook," "initiative," "objective," "designed," "priorities," "goal" or the negative of those words or other similar expressions may identify forward-looking statements that represent our current judgment about possible future events, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Forward-looking statements in this Quarterly Report include statements about, among other things: our ability to consummate our proposed acquisition by XOMA Royalty Corporation (the "Acquisition") or, if we are unable to consummate the Acquisition, to identify and consummat

—FINANC IAL INFORMATION

PART I—FINANC IAL INFORMATION

Financial Statements

Item 1. Financial Statements. Mural Oncology plc and Subsidiaries Condensed Consolidated Ba lance Sheets (Unaudited) September 30, 2025 December 31, 2024 (in thousands) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 58,871 $ 115,462 Marketable securities — 28,923 Receivable from Former Parent — 51 Prepaid expenses 1,212 7,676 Restricted cash 1,711 — Other current assets 364 805 Total current assets 62,158 152,917 Property and equipment, net 466 7,715 Right-of-use assets 3,134 6,783 Restricted cash — 1,969 Other assets — 10 TOTAL ASSETS $ 65,758 $ 169,394 LIABILITIES AND EQUITY CURRENT LIABILITIES: Accounts payable $ — $ 2,056 Accrued expenses 6,790 18,534 Operating lease liabilities—short-term 3,505 5,560 Other current liabilities 235 45 Total current liabilities 10,530 26,195 Operating lease liabilities—long-term 42 2,462 Other liabilities — 235 Total liabilities 10,572 28,892 Commitments and contingencies (Note 10) Preferred shares, nominal value $ 0.01 ; 50,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued or outstanding at September 30, 2025 or December 31, 2024 — — Ordinary shares, nominal value $ 0.01 ; 450,000,000 ordinary shares authorized at September 30, 2025 and December 31, 2024; 17,324,771 and 17,095,371 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 174 171 Additional paid-in capital 299,208 299,682 Unrealized gain on marketable securities — 20 Accumulated deficit ( 244,196 ) ( 159,371 ) Total equity 55,186 140,502 TOTAL LIABILITIES AND EQUITY $ 65,758 $ 169,394 See accompanying notes to the unaudited condensed consolidated financial statements. 4 Mural Oncology plc and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaud

View Full Filing

View this 10-Q filing on SEC EDGAR